The TruSight Oncology 500 product portfolio enables comprehensive genomic profiling (CGP) from both blood and tissue biopsy samples in house. All three assays in the family are designed to identify key biomarkers in guidelines in clinical trials.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec ac libero finibus, volutpat purus id, fermentum quam. Nulla pellentesque massa id ante imperdiet semper. Donec porttitor feugiat egestas. Vivamus vel nibh nibh.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec ac libero finibus, volutpat purus id, fermentum quam. Nulla pellentesque massa id ante imperdiet semper. Donec porttitor feugiat egestas. Vivamus vel nibh nibh.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec ac libero finibus, volutpat purus id, fermentum quam. Nulla pellentesque massa id ante imperdiet semper. Donec porttitor feugiat egestas. Vivamus vel nibh nibh.
Learn how experts across the world have been benefiting from implementing TSO500 assays to enable in-house comprehensive genomic profiling from tissue and liquid biopsies.
Access WebinarsTruSight Oncology 500 | TruSight Oncology 500 High-Throughput | TruSight Oncology 500 ctDNA |
---|---|---|
FFPE (DNA and RNA) | FFPE (DNA and RNA) | Plasma (cfDNA) |
523 genes for DNA variants | 523 genes for DNA variants | 523 genes for DNA variants |
55 genes for RNA variants | 55 genes for RNA variants | |
Variants called: SNVs InDels CNVs Fusions Splice variants |
Variants called: SNVs InDels CNVs Fusions Splice variants |
Variants called: SNVs InDels CNVs Fusions (from DNA) |
Panel size: 1.94Mb DNA; 358kb RNA |
Panel size: 1.94Mb DNA; 358kb RNA | Panel size: 1.94Mb DNA; |
Sequencing Platforms: NextSeq 550Dx (in Research Mode) NextSeq 500/550 |
Sequencing Platforms: NovaSeq 6000 |
Sequencing Platforms: NovaSeq 6000 |
Sample Batching: 8 samples/run |
Sample Batching: 16 – 192 samples/run |
Sample Batching: 8-24 samples/run |
Sample input: 40ng DNA 40ng RNA |
Sample input: 40ng DNA 40-80ng RNA |
Sample input: 30ng cfDNA |
Specificity: 99.9998% |
Specificity: 99.9998% |
Specificity: 99.9995% |
Sensitivity: >96% |
Sensitivity: >96% |
Sensitivity: >95% |
NTRK1 NTRK2 NTRK3 MSI TMB (Emerging) | ||||||||
---|---|---|---|---|---|---|---|---|
Lung | Melanoma | Colon | Ovarian | Breast | Gastric | Bladder | Myeloid | Sarcoma |
AKT1 | BRAF | AKT1 | BRAF | AKT1 | BRAF | MSH5 | ABL1 | ALK |
ALK | CTNNB1 | BRAF | BRCA1 | AR | KIT | PMS2 | ASX1 | APC |
BRAF | GNA11 | HRAS | BRCA2 | BRCA1 | KRAS | TSC1 | CALR | BRAF |
DDR2 | GNAQ | KRAS | KRAS | BRCA2 | MET | CEBPA | CDK4 | |
EGFR | KIT | MET | PDGFRA | ERBB2 | MLH1 | ETV6 | CTNNB1 | |
ERBB2 | MAP2K1 | MLH1 | FOXL2 | FGFR1 | PDGFRA | EZH2 | ETV6 | |
FGFR1 | NF1 | MSH2 | TP53 | FGFR2 | TP53 | FLT3 | EWSR1 | |
FGFR3 | NRAS | MSH6 | PIK3CA | GATA2 | FOXO1 | |||
KRAS | PDGFRA | NRAS | PTEN | IDH1 | GLI1 | |||
MAP2K1 | PIK3CA | PIK3CA | IDH2 | KJT | ||||
MET | PTEN | PMS2 | JAK2 | MDM2 | ||||
NRAS | TP53 | PTEN | KIT | MYOD1 | ||||
PIK3CA | SMAD4 | MPL | NAB2 | |||||
PTEN | TP53 | NPM1 | NF1 | |||||
RET | RUNX1 | PAX3 | ||||||
TP53 | SF3B1 | PAX7 | ||||||
TMB | SRSF2 | PDGFRA | ||||||
TP53 | PDGFRB | |||||||
SDHB | ||||||||
SDHC | ||||||||
SMARCB1 | ||||||||
TFE3 | ||||||||
WT1 |
The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on this page.
* The product to evaluate DNA & RNA variants is the TruSight Oncology 500 DNA/RNA Bundle.
The TruSight Oncology 500 Analytical Evaluation Service is a set of tools intended to guide you in aligning with the latest CAP, AMP, and European standards. We provide recommendations to help you evaluate analytical performance characteristics and integrate products into your workflows.
View ServiceInnovations in molecular assays enable comprehensive, precise analysis of cell-free DNA.
Read Application SpotlightThe next step in precision medicine lies in decentralizing comprehensive biomarker testing.
Read ArticleTruSight Oncology 500 ctDNA assists in detecting low levels of variants in circulating tumor DNA.
Access Webinar to Learn MoreNTRK fusions are rare but important biomarkers linked to response to new TRK inhibitors. Watch CMO Phil Febbo and Maude Champagne walk through these advances in fusion detection.
Access WebinarNow providing customers with a versatile, scalable, sample-to-report workflow.
Illumina and the Frederick National Laboratory are working together to establish clinical utility for liquid biopsies.
TruSight Oncology 500 products offer deep, comprehensive, and accessible sequencing power for detecting tumor biomarkers.